Abstract:The general goals of diabetes treatment are to maintain optimal individualized glycemic targets and to prevent complications. Today, there are significant barriers to successful diabetes therapy, such as parenteral drug administration, decreased therapeutic efficacy after an initial improvement in glycemia, inaccessibility of new medicines in lower-income countries, and high drug prices. Accordingly, significant research attention has been devoted to the development of a cheap and comfortable antidiabetic agent, which demonstrates success in lowering blood glucose levels as well as fewer toxicity properties. In recent years, the effects of inorganic and organic vanadium compounds have been investigated in diabetes treatment. These studies have found the low bioavailability of orally administered inorganic vanadium salts; thus, effective doses to reduce blood glucose levels to normal may cause serious adverse events. In addition, the only study with an organo-vanadium compound (bis(maltolato)oxovanadium(IV)), which has reached Phase IIa clinical trial, was terminated after three months due to renal complications. Moreover, despite a growing interest in polyoxovanadates for treating diabetes in the last few years, the toxic potentials of these compounds are still unknown. However, the precise mechanism of their antidiabetic actions remains unclear. A broad spectrum of possible mechanisms and hypotheses, such as enhancement of insulin secretion and enhanced sensitivity to insulin, as well as suppression of hepatic glucose production and decrease of intestinal glucose absorption, have been presented. In conclusion, besides the promising results obtained in animal and human studies, no vanadium compound has successfully reduced blood glucose with acceptable safety and tolerability. More studies of vanadium benefit-risk could lead to a new era in vanadium biomedicine.

A Novel PTP1b Inhibitor Vanadium-Flavone Complex: Synthesis and Pharmacodynamic Evaluation in Streptozotocin-Induced Diabetic Mice

Synthesis, characterization and anti-diabetic therapeutic potential of novel aminophenol-derivatized nitrilotriacetic acid vanadyl complexes

Synthesis And Anti-Diabetic Activity Of New N,N-Dimethylphenylenediamine-Derivatized Nitrilotriacetic Acid Vanadyl Complexes

The Molecular Mechanisms and Rational Design of Anti-Diabetic Vanadium Compounds.

Synthesis, Characterization and Anti-Diabetic Therapeutic Potential of a New Benzyl Acid-Derivatized Kojic Acid Vanadyl Complex

A New Oxovanadium Complex Enhances Renal Function by Improving Insulin Signaling Pathway in Diabetic Mice.

Inhibitory Activities of Some Oxovanadium Complexes with N-Heterocyclic Ligands against PTP1B/ALP

Effects of Bis(α-Furancarboxylato)oxovanadium(iv) on Glucose Metabolism in Fat-Fed/streptozotocin-diabetic Rats

A New Orally Active Antidiabetic Vanadyl Complex – Bis(α-Furancarboxylato)oxovanadium(iv)

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

A Dioxidovanadium (V) Complex of NNO-donor Schiff Base As a Selective Inhibitor of Protein Tyrosine Phosphatase 1B: Synthesis, Characterization, and Biological Activities

Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties

Synthesis and Characterization of Oxidovanadium Complexes As Enzyme Inhibitors Targeting Dipeptidyl Peptidase IV.

Vanadium Compounds Modulate PPARγ Activity Primarily by Increasing PPARγ Protein Levels in Mouse Insulinoma NIT-1 Cells

Therapeutic Effect of Vanadyl Rosiglitazone on Diabetic Mice

Effects of insulin-mimetic vanadyl-poly(γ-glutamic acid) complex on diabetic rat model

Effects of insulin-mimetic vanadyl-poly(gamma-glutamic acid) complex on diabetic rat model.

Vanadium compounds: New potential antidiabetic drugs

Insulin Like Activity and Mechanism of Vanadium Complex

In Vivo Insulin-Mimetic Activity of [N,n′-1,3-propyl-bis(salicyladimine)]oxovanadium(iv)

Ternary Oxovanadium(iv) Complexes of ONO-donor Schiff Base and Polypyridyl Derivatives As Protein Tyrosine Phosphatase Inhibitors: Synthesis, Characterization, and Biological Activities